Ranbaxy recalls Generic Lipitor in US due to dose mix-up
The FDA classified the recall as Class II, which is reserved for situations in which a product may cause temporary or medically reversible health problems, or where the probability of a serious health problem is remote. This is the third recall of the same drug over the past two years. The company had recalled 480,000 bottles of the cholesterol lowering medicine in November, 2012 after it discovered contamination with tiny glass particles. This recall instigated Ranbaxy to suspend production while it fixed the problem; the company resumed production last year. The newly recalled bottles were distributed in 2012 and have expiration dates of May 2014.
A Ranbaxy spokesman said that the company hasn't received any complaints about the recalled batches and the recall is being conducted at the retail level. The company is proactively recalling the lots out of an abundance of caution, keeping the safety of its patients in mind and with the full knowledge of the US FDA.